Company’s 36-month beta value is 0.42.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 4 as “overweight,” 18 as “hold,” and 1 as “sell.”
The public float for BMY is 2.03B, and currently, short sellers hold a 1.51% ratio of that floaft. The average trading volume of BMY on March 24, 2025 was 10.98M shares.
BMY) stock’s latest price update
The stock price of Bristol-Myers Squibb Co (NYSE: BMY) has jumped by 1.08 compared to previous close of 60.42. Despite this, the company has seen a gain of 3.49% in its stock price over the last five trading days. seekingalpha.com reported 2025-03-21 that Merck and Bristol-Myers Squibb occupy leading positions in the cancer therapy market. Each of them has advantages, as well as dark spots in the portfolio of medications relative to the comparator. In this article, dear Seeking Alpha readers, you will learn whether Merck or Bristol-Myers Squibb is a more promising stock in the long term.
BMY’s Market Performance
Bristol-Myers Squibb Co (BMY) has experienced a 3.49% rise in stock performance for the past week, with a 9.46% rise in the past month, and a 5.93% rise in the past quarter. The volatility ratio for the week is 2.15%, and the volatility levels for the past 30 days are at 2.60% for BMY.. The simple moving average for the past 20 days is 2.00% for BMY’s stock, with a 16.69% simple moving average for the past 200 days.
Analysts’ Opinion of BMY
Many brokerage firms have already submitted their reports for BMY stocks, with Jefferies repeating the rating for BMY by listing it as a “Buy.” The predicted price for BMY in the upcoming period, according to Jefferies is $70 based on the research report published on December 16, 2024 of the previous year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see BMY reach a price target of $63. The rating they have provided for BMY stocks is “Neutral” according to the report published on December 10th, 2024.
BMY Trading at 4.90% from the 50-Day Moving Average
After a stumble in the market that brought BMY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -3.57% of loss for the given period.
Volatility was left at 2.60%, however, over the last 30 days, the volatility rate increased by 2.15%, as shares surge +9.39% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +6.88% upper at present.
During the last 5 trading sessions, BMY rose by +3.49%, which changed the moving average for the period of 200-days by +46.21% in comparison to the 20-day moving average, which settled at $59.87. In addition, Bristol-Myers Squibb Co saw 7.97% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BMY starting from BOERNER CHRISTOPHER S., who purchase 2,000 shares at the price of $55.05 back on Feb 20 ’25. After this action, BOERNER CHRISTOPHER S. now owns 104,626 shares of Bristol-Myers Squibb Co, valued at $110,096 using the latest closing price.
Hirawat Samit, the EVP,Chief Med.Offr.,Drug Dev. of Bristol-Myers Squibb Co, purchase 1,823 shares at $54.84 during a trade that took place back on Feb 14 ’25, which means that Hirawat Samit is holding 63,932 shares at $100,000 based on the most recent closing price.
Stock Fundamentals for BMY
Current profitability levels for the company are sitting at:
- 0.18 for the present operating margin
- 0.67 for the gross margin
The net margin for Bristol-Myers Squibb Co stands at -0.19. The total capital return value is set at 0.13. Equity return is now at value -39.10, with -9.53 for asset returns.
Based on Bristol-Myers Squibb Co (BMY), the company’s capital structure generated 0.76 points at debt to capital in total, while cash flow to debt ratio is standing at 0.3. The debt to equity ratio resting at 3.13. The interest coverage ratio of the stock is 4.43.
Currently, EBITDA for the company is 3.17 billion with net debt to EBITDA at 12.94. When we switch over and look at the enterprise to sales, we see a ratio of 3.41. The receivables turnover for the company is 4.34for trailing twelve months and the total asset turnover is 0.52. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.25.
Conclusion
In a nutshell, Bristol-Myers Squibb Co (BMY) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
